Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Initial Clinical Activity And Safety Profile In Phase 1 Trial
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics' SMARCA2 degrader, PRT3789, shows promising initial clinical activity and safety in a Phase 1 trial, particularly in patients with SMARCA4-mutated NSCLC and esophageal cancer. The drug was well-tolerated with no serious adverse events. An investor call is scheduled for September 13, 2024.
September 13, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prelude Therapeutics' PRT3789 demonstrated promising clinical activity and safety in a Phase 1 trial, showing potential in treating SMARCA4-mutated cancers. The drug was well-tolerated with no serious adverse events.
The positive initial clinical activity and safety profile of PRT3789 in a Phase 1 trial is likely to boost investor confidence in Prelude Therapeutics. The absence of serious adverse events and the observed anti-tumor activity in specific cancer types are significant milestones that could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100